公开(公告)号：WO1991010427A2

公开(公告)日：1991-07-25

申请号：PCT/US1990007697

申请日：1990-12-31

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS ,  THE UNIVERSITY OF SOUTH FLORIDA ,  MEHTA, Kapil ,  RAO, Undaru, R. ,  VICKERY, Ann, C.

Inventor： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS ,  THE UNIVERSITY OF SOUTH FLORIDA

IPC: A61K31/13

CPC classification number: A61K31/415 ,  A61K31/00 ,  A61K31/13 ,  A61K31/14 ,  A61K31/16 ,  A61K31/18 ,  Y02A50/421

Abstract: A method is described for blocking maturation and production of microfilariae in adult filarial nematodes utilizing a transglutaminase inhibitor, such as monodansyl cadaverine (MDC). Experiments applying this method to several Brugia filarial infections, including Brugia malayi, were successful. Higher concentration of transglutaminase inhibitor proved to be filariacidal.

Abstract translation: 本发明涉及一种用于抑制成熟和产量在成年阶段的丝类型的线虫微丝蚴，以及转谷氨酰胺酶或反馈的由转谷氨酰胺酶发送的抑制通过一种方法 使用转谷氨酰胺酶抑制剂阻断成人生物体对微丝蚴成熟和产生并杀死成虫生物体。 已经证明应用这种方法来治疗布鲁氏菌蠕虫感染的实验，包括Brugia malayi蠕虫，是有效的。 较高浓度的转谷氨酰胺酶抑制剂证明了对独立于宿主或宿主生物体内的成年生物体具有上述的细丝作用。

公开(公告)号：WO2015195941A1

公开(公告)日：2015-12-23

申请号：PCT/US2015/036471

申请日：2015-06-18

Applicant: THE CHARLES STARK DRAPER LABORATORY, INC. ,  THE UNIVERSITY OF SOUTH FLORIDA

Inventor： MAHER, Steven ,  SAADI, Wajeeh M. ,  TAYLOR, Amy Jane ,  SUN, Hoi-Cheong Steve ,  KYLE, Dennis ,  ADAMS, John

IPC: C12M1/32

CPC classification number: C12M23/12 ,  B29C39/026 ,  B29K2071/00 ,  B29L2031/752 ,  C08G65/4012 ,  C08G73/10 ,  C08G77/04 ,  C09D163/00 ,  C09D175/04 ,  C12M23/22

Abstract: This disclosure provides micro-feature devices and methods for fabricating micro-feature devices. A micro-feature device can include a substantially rigid transparent substrate. The device can include a plurality of macrowells defined in the transparent substrate. Each macrowell can have a width in the range of about one millimeter to about 35 millimeters and a depth in the range of about two millimeters to about 12 millimeters. Each macrowell can include a respective plurality of microwells defined in a respective lower surface of the macrowell. Each microwell can have a width in the range of about 50 microns to about 500 microns and a depth in the range of about 50 microns to about 500 microns.

Abstract translation: 本公开提供了用于制造微特征器件的微特征器件和方法。 微特征装置可以包括基本刚性的透明基板。 该装置可以包括限定在透明基板中的多个孔眼。 每个大孔径可以具有在约1毫米至约35毫米范围内的宽度和在约2毫米至约12毫米范围内的深度。 每个小孔可以包括限定在大圆盘的相应下表面中的相应的多个微孔。 每个微孔可以具有在约50微米至约500微米范围内的宽度和约50微米至约500微米范围内的深度。

公开(公告)号：WO2013116834A2

公开(公告)日：2013-08-08

申请号：PCT/US2013/024626

申请日：2013-02-04

Applicant: THE CHARLES STARK DRAPER LABORATORY, INC. ,  THE UNIVERSITY OF SOUTH FLORIDA ,  ACHYUTA, Anilkumar Harapanahalli ,  CUEVAS, Javier ,  SUNDARAM, Shankar ,  KATNIK, Chris

Inventor： ACHYUTA, Anilkumar Harapanahalli ,  CUEVAS, Javier ,  SUNDARAM, Shankar ,  KATNIK, Chris

IPC: G01N33/50

CPC classification number: G01N33/5058 ,  C12M23/16 ,  C12M35/02 ,  C12M35/08 ,  C12M41/34 ,  G01N21/6486 ,  G01N33/5005 ,  G01N33/5023 ,  G01N33/5026 ,  G01N2333/525 ,  G01N2333/5428 ,  G01N2333/545 ,  G01N2500/10 ,  G01N2510/00

Abstract: This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels.

Abstract translation: 该应用程序提供了用于建模缺血性卒中病症的装置。 该装置可用于培养神经元，并将神经元的第一群体置于低氧条件下，将第二群神经元置于常氧条件下。 神经元在多孔屏障上培养，并且在屏障的另一侧运行一个或多个流体填充的通道。 通过流过具有不同氧水平的流体通过通道，可以将所需的氧浓度递送到最靠近这些通道的细胞。

公开(公告)号：WO2008011046A2

公开(公告)日：2008-01-24

申请号：PCT/US2007/016239

申请日：2007-07-16

Applicant: THE H.LEE MOFFITT CANCER AND RESEARCH INSTITUTE, INC. ,  THE UNIVERSITY OF SOUTH FLORIDA ,  YEATMAN, Timothy ,  DALTON, William, S.

Inventor： YEATMAN, Timothy ,  DALTON, William, S.

IPC: G06F19/00

CPC classification number: G06Q50/24 ,  G06F19/00 ,  G06Q50/22 ,  G16H10/20 ,  G16H10/60

Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects. The discriminating set of cellular constituents is identified from those cellular constituents in the plurality of cellular constituents whose measurement values discriminates between the responder and nonresponder sets of biological samples.

Abstract translation: 提供了用于识别临床试验的多个受试者的计算机，计算机程序产品和方法。 识别存储的多个分子谱中的一组候选分子谱。 每个这样的概况都具有用于识别一组细胞成分的测量结果，该组细胞成分匹配生物样本的响应组中的对应细胞成分的测量结果，从而从衍生出候选分子谱集的那些受试者识别用于试验的多个受试者 。 所存储的多个分布图中的每个相应的分子图谱具有对从第一多个受试者获得的多个样品中来自各个生物样品的多个细胞成分的测量结果。 从其多个细胞成分中的那些细胞成分中鉴别出一组细胞成分，其测量值区分响应者组和无响应者组的生物样品。

公开(公告)号：WO2002036166A3

公开(公告)日：2002-05-10

申请号：PCT/US2001/042909

申请日：2001-11-05

Applicant: THE UNIVERSITY OF SOUTH FLORIDA ,  TAN, Jun ,  TOWN, Terrence ,  MULLAN, Michael

Inventor： TAN, Jun ,  TOWN, Terrence ,  MULLAN, Michael

IPC: A61K39/395

Abstract: A method of inhibiting the negative effects of beta-amyloid in the brain of an animal comprising administering an effective amount of a compound that modulates CD45 activity. This invention also relates to compositions for use in stimulating CD45, and assays for une in finding compounds useful in inhibiting the negative effects of beta-amyloid. An assay for use in identifying compounds that inhibit the negative effects of beta-amyloid comprises (a) contacting immune cells with a predetermined amount of one or more test compounds in the presence of beta-amyloid or one or more peptides derived therefrom, (b) monitoring the amount of one or more inflammatory molecules released by the immune cells, and (c) comparing the amount found in step (b) with another amount found in the absence of the one or more test compounds or using a different predetermined amount the one or more test compounds.